Grifols: Another solid quarter but upside looks more tiny

BUY, Fair Value EUR32.5 (+7%)

News published on November Wednesday 6, 2013
Share on

Grifols released a solid set of numbers in Q3 with sales growth accelerating 9.3% CER versus 5.3% CER in H1 driven by a strong performance in the BioScience division, up 11.2% CER in the quarter. Demand for plasma derivatives products remained very dynamic especially for Albumin and Alpha-1-antitrypsin, both growing double-digits. 9M adjusted EBITDA margin was flat versus H1 at 33.7% but up 140bps versus 9M 2012, positively impacted by productivity gains (gross margin up 110bps versus 9M 2012). 9M net profit is significantly up at EUR267m (+35.3%) with lower tax expenses as well as more favourable interest expenses (EUR-29m versus last year).

Full report available to subscribers
Please contact   

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities